A Malignant Alliance

Two proteins interact to save adhesion molecules from degradation, potentially contributing to a more aggressive cancer.

Written byMegan Scudellari
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

INTEGRIN TRAP: Rab25 proteins bind integrins in the cell membrane and shuttle them to lysosomes. If the Rab25 shuttles the integrins to a lysosome where CLIC3 is absent, then they are degraded (A). If CLIC3 is present on the surface of the lysosome, the integrins survive and are shuttled to the rear of the cell where they help the cell detach from the extracellular matrix (ECM) and become metastatic (B). PRECISION GRAPHICS

Rab25 has perplexed cancer researchers for years. The small membrane-trafficking enzyme sometimes appears to drive cancer and at other times to protect against it: it is associated with aggression in breast and ovarian cancer and with suppression of intestinal tumors. Intrigued by this contradiction, Jim Norman and colleagues at the Beatson Institute for Cancer Research in Glasgow screened Rab25-expressing cells for additional proteins that might be involved in its function.

That screen showed that chloride intracellular channel protein 3 (CLIC3) was the most significantly upregulated gene in cultured Rab25-expressing cells. Using biochemical approaches, the team found that both Rab25 and CLIC3 control the intracellular transport of integrins—transmembrane proteins that attach a cell’s cytoskeleton to the extracellular matrix (ECM) and send signals between the two. Integrins ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies